Study of Acute and Chronic Myocardiac Lesions Angiogenesis by 68Ga-NODAGA-RGD Cardiac PET
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Myocardial Infarction, Acute
- Sponsor
- University of Lausanne Hospitals
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- 82Rb PET/CT : assessment of change of myocardial blood flow reserve at rest and at stress
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
The study is about exploring physiological angiogenesis linked to tissue repair in patients with acute heart infarction or chronic heart ischemia by means of 68Ga-NODAGA-RGD PET/CT imaging.
Detailed Description
Several animal studies have demonstrated the expression of αvβ3 integrins on the surface of the endothelium present in neovessels in formation, especially during neoangiogenesis after myocardial ischemic injury. 68Ga-NODAGA-RGD is a positron-emission-tomography (PET) ligand targeted towards αvβ3 integrins. αvβ3 integrins could potentially act as a biomarker for the follow-up of heart infarction. In the present study, 68Ga-NODAGA-RGD PET/CT imaging is a tool to understand and evaluate tissue repair after heart lesion and its evolution allowing a better management of patients with occluded artery. Three groups of patients are included : patients with acute infarction, patients with acute infarction requiring reperfusion treatment and patients with chronic ischemic occlusion. Each patient would benefit from a 82Rb (82rubidium) PET/CT as part of standard management and from a 68Ga-NODAGA-RGD PET/CT as part of the present study. Patients from groups 1 and 2 will have 3 sets of both exams : one after the ischemic event, one at one month and another at 3 months post event. Patients form group 3 will have a set of both exams before reperfusion treatment and one at 2 months after reperfusion.
Investigators
John O. Prior
PhD, MD, Head of Nuclear Medicine Department
University of Lausanne Hospitals
Eligibility Criteria
Inclusion Criteria
- •patients with acute infarction or patients with acute infarction requiring reperfusion treatment or patients with chronic ischemic occlusion
- •Karnofsky ≥ 80%
- •signed informed consent
Exclusion Criteria
- •pregnancy, breastfeeding
- •claustrophobia
- •contra-indication to adenosine administration
- •lack of discernment to sign informed consent
Outcomes
Primary Outcomes
82Rb PET/CT : assessment of change of myocardial blood flow reserve at rest and at stress
Time Frame: at 1, 4 and 12 weeks post ischemic events for patients of groups 1 and 2 - Before and 2 months after reperfusion treatment for patients of group 3
mL/min/g
82Rb PET/CT : assessment of change of myocardial blood flow at rest and at stress
Time Frame: at 1, 4 and 12 weeks post ischemic events for patients of groups 1 and 2 - Before and 2 months after reperfusion treatment for patients of group 3
mL/min/g
82Rb PET/CT : assessment of change of difference of myocardial blood flow at stress and at rest
Time Frame: at 1, 4 and 12 weeks post ischemic events for patients of groups 1 and 2 - Before and 2 months after reperfusion treatment for patients of group 3
mL/min/g
68Ga-NODAGA PET/CT : assessment of change of standard uptake value (SUV)
Time Frame: at 1, 4 and 12 weeks post ischemic events for patients of groups 1 and 2 - Before and 2 months after reperfusion treatment for patients of group 3
g/ml